Cefuroxime pharmacokinetics in continuous and intermittent peritoneal dialysis. 1985

M K Chan, and A K Browning, and C J Poole, and L A Matheson, and C S Li, and R A Baillod, and J F Moorhead

Pharmacokinetics of cefuroxime was studied in patients on continuous ambulatory or intermittent peritoneal dialysis. A single intravenous bolus (15 mg/kg) of cefuroxime provided a mean serum concentration of 86 mg/litre 5 min, 40 mg/litre 1 h, 163 mg/litre 24 h after the injection. The peritoneal clearance of cefuroxime varied widely among different individuals, ranging from 1.45 to 6.17 ml/min with a mean of 3.59 ml/min during 4-hour exchanges, and from 0,52 to 11.3 ml/min during 2-hour exchanges. A single injection (15 mg/kg) of the antibiotic could not provide satisfactory antibiotic concentrations in peritoneal effluent during peritoneal lavage. When cefuroxime had been added to peritoneal dialysis solution before the solution was instilled into the peritoneal cavity, a significant decrease in cefuroxime concentration occurred in the peritoneal effluent even after a short equilibration time. Furthermore, cefuroxime concentrations measured in residual dialysis solutions in the plastic bags ranged from 44.3 to 1,351% of the concentration of cefuroxime calculated from the added doses, indicating that despite great care, mixing of the antibiotic with dialysis solutions in plastic bags was far from uniform.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010530 Peritoneal Dialysis Dialysis fluid being introduced into and removed from the peritoneal cavity as either a continuous or an intermittent procedure. Dialyses, Peritoneal,Dialysis, Peritoneal,Peritoneal Dialyses
D010531 Peritoneal Dialysis, Continuous Ambulatory Portable peritoneal dialysis using the continuous (24 hours a day, 7 days a week) presence of peritoneal dialysis solution in the peritoneal cavity except for periods of drainage and instillation of fresh solution. CAPD,Continuous Ambulatory Peritoneal Dialysis
D010538 Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs. Primary Peritonitis,Secondary Peritonitis,Peritonitis, Primary,Peritonitis, Secondary
D002444 Cefuroxime Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS. Cephuroxime,Ketocef,Zinacef
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D005260 Female Females

Related Publications

M K Chan, and A K Browning, and C J Poole, and L A Matheson, and C S Li, and R A Baillod, and J F Moorhead
January 1985, Revue de l'infirmiere,
M K Chan, and A K Browning, and C J Poole, and L A Matheson, and C S Li, and R A Baillod, and J F Moorhead
January 1988, Srpski arhiv za celokupno lekarstvo,
M K Chan, and A K Browning, and C J Poole, and L A Matheson, and C S Li, and R A Baillod, and J F Moorhead
January 1999, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,
M K Chan, and A K Browning, and C J Poole, and L A Matheson, and C S Li, and R A Baillod, and J F Moorhead
February 1982, International journal of clinical pharmacology, therapy, and toxicology,
M K Chan, and A K Browning, and C J Poole, and L A Matheson, and C S Li, and R A Baillod, and J F Moorhead
November 1984, American journal of kidney diseases : the official journal of the National Kidney Foundation,
M K Chan, and A K Browning, and C J Poole, and L A Matheson, and C S Li, and R A Baillod, and J F Moorhead
October 1980, Annals of internal medicine,
M K Chan, and A K Browning, and C J Poole, and L A Matheson, and C S Li, and R A Baillod, and J F Moorhead
November 1988, Clinical nephrology,
M K Chan, and A K Browning, and C J Poole, and L A Matheson, and C S Li, and R A Baillod, and J F Moorhead
July 1981, Clinical nephrology,
M K Chan, and A K Browning, and C J Poole, and L A Matheson, and C S Li, and R A Baillod, and J F Moorhead
January 1977, Journal of dialysis,
M K Chan, and A K Browning, and C J Poole, and L A Matheson, and C S Li, and R A Baillod, and J F Moorhead
January 1981, Clinical and experimental dialysis and apheresis,
Copied contents to your clipboard!